tucatinib,pertuzumab,trastuzumab
roche,seagen
as we gear up to hear about #her2 #colorectalcancer lba #wcgic2022 on the #mountaineer study, see intriguing story of her2 resistances. erbb2 mutation that abolishes pertuzumab binding eradicated with t-dxd cancer becomes her2 now responding to egfr 
Oncologist | Researcher | ColorectalCancer #CRCSM???????@MayoClinic @PittTweet Alum; ??#ctDNA #LiquidBiopsies??#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22